Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • Immune Environment in Glioblastoma (Upcoming)
    • Korsmeyer Award 25th Anniversary Collection (Jan 2023)
    • Aging (Jul 2022)
    • Next-Generation Sequencing in Medicine (Jun 2022)
    • New Therapeutic Targets in Cardiovascular Diseases (Mar 2022)
    • Immunometabolism (Jan 2022)
    • Circadian Rhythm (Oct 2021)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Commentaries
    • Research letters
    • Letters to the editor
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • In-Press Preview
  • Commentaries
  • Research letters
  • Letters to the editor
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Alerts
  • Advertising
  • Job board
  • Subscribe
  • Contact

Submit a comment

Adenylate cyclase of human fat cells. Expression of epinephrrine-sensitive activation revealed by 5'guanylyl-imidodiphosphate.
B Cooper, … , J S Partilla, R I Gregerman
B Cooper, … , J S Partilla, R I Gregerman
Published November 1, 1975
Citation Information: J Clin Invest. 1975;56(5):1350-1353. https://doi.org/10.1172/JCI108214.
View: Text | PDF
Research Article

Adenylate cyclase of human fat cells. Expression of epinephrrine-sensitive activation revealed by 5'guanylyl-imidodiphosphate.

  • Text
  • PDF
Abstract

Although catecholamines stimulate lipolysis in human fat cells, activation by epinephrine of adenylate cyclase in human fat cell membranes is not readily observed. The possible role of guanine nucleotides in this reaction has now been examined with human material. Fat cell ghosts were prepared from subcutaneous fat obtained from patients undergoing elective surgery. Adenylate cyclase was assayed with [alpha-32P]ATP as substrate. Fluoride ion stimulated the enzyme 8.3-fold relative to basal levels, but epinephrine activation of cyclase was not statistically significant. GTP did not allow expression of an epinephrine effect. However, the addition of the GTP analogue, 5'-guanylyl-imidodiphosphate [GMP-P(NH)P], along with epinephrine produced 5.7-fold activation of the enzyme (P less than 0.001). GMP-P(NH)P alone was without stimulatory effect. Comparable augmentation by GMP-P (NH) P of adenylate cyclase activity was seen with isoproterenol, norepinephrine, and epinephrine. Propranolol blocked catecholamine-GMP-P (NH) P stimulation of the enzyme, suggesting that the nucleotide-dependent activation of catecholamine-sensitive adenylate cyclase is mediated by beta-receptors. GMP-P(NH)P may prove useful in allowing in vitro demonstration of additional hormone-sensitive adenylate cyclase systems.

Authors

B Cooper, J S Partilla, R I Gregerman

×

Guidelines

The Editorial Board will only consider comments that are deemed relevant and of interest to readers. The Journal will not post data that have not been subjected to peer review; or a comment that is essentially a reiteration of another comment.

  • Comments appear on the Journal’s website and are linked from the original article’s web page.
  • Authors are notified by email if their comments are posted.
  • The Journal reserves the right to edit comments for length and clarity.
  • No appeals will be considered.
  • Comments are not indexed in PubMed.

Specific requirements

  • Maximum length, 400 words
  • Entered as plain text or HTML
  • Author’s name and email address, to be posted with the comment
  • Declaration of all potential conflicts of interest (even if these are not ultimately posted); see the Journal’s conflict-of-interest policy
  • Comments may not include figures
This field is required
This field is required
This field is required
This field is required
This field is required
This field is required

Copyright © 2023 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts